| Literature DB >> 34065175 |
Aswir Abd Rashed1, Devi-Nair Gunasegavan Rathi1.
Abstract
The utilization of therapeutic plants is expanding around the globe, coupled with the tremendous expansion of alternative medicine and growing demand in health treatment. Plants are applied in pharmaceuticals to preserve and expand health-physically, mentally and as well as to treat particular health conditions and afflictions. There are more than 600 families of plants identified so far. Among the plants that are often studied for their health benefit include the genus of Salvia in the mint family, Lamiaceae. This review aims to determine the bioactive components of Salvia and their potential as antidiabetic agents. The search was conducted using three databases (PubMed, EMBASE and Scopus), and all relevant articles that are freely available in the English language were extracted within 10 years (2011-2021). Salvia spp. comprises many biologically active components that can be divided into monoterpenes, diterpenes, triterpenes, and phenolic components, but only a few of these have been studied in-depth for their health benefit claims. The most commonly studied bioactive component was salvianolic acids. Interestingly, S. miltiorrhiza is undoubtedly the most widely studied Salvia species in terms of its effectiveness as an antidiabetic agent. In conclusion, we hope that this review stimulates more studies on bioactive components from medicinal plants, not only on their potential as antidiabetic agents but also for other possible health benefits.Entities:
Keywords: Salvia; antidiabetic; bioactive components; human health
Year: 2021 PMID: 34065175 PMCID: PMC8161164 DOI: 10.3390/molecules26103042
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Hydrolysis of starch to glucose as catalyzed by α-amylase and α-glucosidase (adapted from [23]).
Bioactive components of Salvia spp. and their antidiabetic potential.
| Ref. | Objective | Methods | Findings | Conclusion |
|---|---|---|---|---|
| [ | To identify the antidiabetic compounds and α-amylase inhibitors from |
Extraction, chromatography and spectroscopy Antidiabetic activity: α-amylase |
Ethanol extract of The chromatographical analysis detected flavonoid compounds (chrysoeriol) Chrysoeriol inhibited the α-amylase activity (IC50 = 1.27 (1.21–1.33) mM |
Isolation and identification of flavone compound, chrysoeriol |
| [ | To explore the phytochemical composition, inhibitory enzyme potential, and antioxidant activities of |
Extraction and chemical profiling Antidiabetic activity: α-amylase and α-glucosidase |
Ultrasonication-assisted extraction (UAE) extract possessed the highest phenolic and flavonoid contents (111.41 mg gallic acid and 23.46 mg rutin equivalent/g extract) α-glucosidase inhibition (1.61–1.65 mmol acarbose equivalent (ACAE)/g) and α-amylase inhibition (0.56–0.73 mmol ACAE/g) |
Possible therapeutic application of |
| [ | To investigate the volatile oil composition of the leaves and flowers and to evaluate the antidiabetic enzyme inhibitory assays of the oils and several extracts of |
Extraction and chemical profiling Antidiabetic activity: α-glucosidase and α-amylase |
Leaves essential oil (EO) was rich in ester compounds Flowers EO was rich in 6,10,14-trimethyl-2-pentadecanone (55.7%) Antidiabetic potential (IC50 = 8–145 μg/mL) Methanol extract has the strongest α-amylase and α-glucosidase inhibitory activities (IC50 = 24 and 8.3 μg/mL, respectively) |
The methanol extract exhibited remarkable antidiabetic potential |
| [ | To evaluate the antidiabetic activities of |
Extraction and chemical profiling of EO Antidiabetic activity: α-glucosidase and α-amylase |
The major compound: spathulenol (87.4%) The most abundant phenolic components: rutin, quercetin, apigenin, rosmarinic acid (RA), and ferulic acid EO exhibited the strongest activity (IC50 = 1.18 mg/mL and 1.54 mg/mL in α-glucosidase and α-amylase assays |
|
| [ | To evaluate the chemical composition and enzyme inhibitory activity of |
Extraction and chemical profiling Antidiabetic activity: α-glucosidase |
The major compound: RA (7584 μg/g extract) The major components in EO: oxygenated sesquiterpenes Methanolic extract showed the strongest α-glucosidase inhibitory activity (IC50 = 19 mg/mL) |
|
| [ | To evaluate simultaneous determination and quantification of ursolic acid and oleanolic acid in 14 |
Extraction and compound separation Antidiabetic activity: α-glucosidase |
Ursolic acid (0.21–9.76 mg/g) and oleanolic acid (0.20–12.7 mg/g) α-Glucosidase activity (IC50 = 17.6 to 173 µg/mL) The best α-glucosidase inhibitory activities with the lowest IC50 values, 17.6 and 25.9 μg/mL: The two lowest active samples with the IC50 values of 162 μg/mL and 173 μg/mL: |
A strong correlation between both ursolic and oleanolic contents of extracts and inhibition effects on α-glucosidase activity was detected Anatolian |
| [ | To evaluate the effect of SalA on diabetic vascular endothelial dysfunction (VED) |
STZ-induced diabetic rats were treated with SalA (1 mg/kg, 90% purity) orally for 10 weeks after modeling and were given a high-fat diet (HFD) Serum indications, contractile and relaxant responses of aorta rings |
Reduction in serum malondialdehyde (MDA), aortic advanced glycation end products (AGEs), nitric oxide synthase (NOS) activity and expression of endothelial NOS protein |
SalA could protect against vascular VED in diabetes |
| [ | To investigate the protective effects of SalA on the peripheral nerve in diabetic rats |
STZ-induced diabetic rats were treated with SalA (0.3, 1 and 3 mg/kg, ig) for 8 weeks Peripheral nerve function via paw withdrawal mechanical threshold (PWMT) and motor nerve conduction velocity (MNCV) Expression of biomarkers |
Increased PWMT, MNCV, AMP-activated protein kinase (AMPK) phosphorylation, upregulated peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1α), silent information regulator protein3 (Sirt3) and neuronal NOS expression, but had no influence on liver kinase B1 (LKB1) |
SalA has protective effects against diabetic neuropathy |
| [ | To investigate the in vivo and in vitro antidiabetic effect of SalA and the underlying mechanisms |
Alloxan-induced type 1 diabetic mice and STZ-induced type 2 diabetic rats received SalA treatment Measurement of glucose consumption and mitochondrial function Determination of AMPK and protein kinase B (Akt) |
Reduced fasting blood glucose (FBG), fed blood glucose and enhanced glucose uptake Improved hepatic and skeletal muscle mitochondrial function Activated AMPK phosphorylation through Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ)/AMPK signaling pathway No effect on insulin secretagogue and activation of PI3K/Akt signaling pathway |
SalA exhibits antidiabetic effects |
| [ | To evaluate the antidiabetic effect of SalB in multiple low-dose STZ-induced diabetes in rat |
STZ-induced diabetic rats were treated with SalB at doses of 20 or 40 mg/kg for 3 weeks Measurement of serum glucose, insulin level and some oxidative stress markers Oral glucose tolerance test (OGTT), histological assessment, and apoptosis determination |
SalB20 and SalB40 significantly decreased serum glucose and improved OGTT Serum insulin was significantly higher in SalB20- and Sal B40-treated diabetics SalB40 treatment significantly lowered MDA, raised glutathione (GSH), catalase activity The number of pancreatic islets and their area was significantly higher in the SalB40-treated diabetic group versus diabetics |
Three-week treatment of diabetic rats with SalB exhibited Antidiabetic activity |
| [ | To investigate the effects of SalB on diabetes-related metabolic changes in a spontaneous model of T2DM, as well as its potential molecular mechanism |
Male C57BL/KsJ-db/db mice were orally treated with SalB (50 and 100 mg/kg) or metformin (positive drug, 300 mg/kg) for 6 weeks. Measurement of glucose tolerance, insulin tolerance, fasting blood glucose, serum lipids, insulin levels, and glycogen content in muscle |
SalB decreased FBG, serum insulin, reduced hepatic gluconeogenic gene expression and improved insulin intolerance in db/db mice SalB100 significantly improved glucose intolerance, increased hepatic glycolytic gene expression and muscle glycogen content and ameliorated histopathological alterations of the pancreas Increased phosphorylated (p-AMPK) protein expression in skeletal muscle and liver, glucose transporter 4 (GLUT4) and glycogen synthase protein expressions in skeletal muscle, peroxisome proliferator-activated receptor alpha (PPARα) and phosphorylated acetyl CoA carboxylase (p-ACC) protein expressions in the liver |
SalB displays beneficial effects in the prevention and treatment of T2DM |
| [ | To investigate the effects of SalB on glycometabolism, lipid metabolism, insulin resistance, oxidative stress, and glycogen synthesis in the T2DM rat model |
HFD and STZ-induced diabetic rats were randomly divided into the model group, SalB subgroups (50, 100, and 200 mg/kg), and rosiglitazone group |
SalB100 and SalB200 significantly decreased blood glucose and insulin, and increased insulin sensitivity index (ISI) SalB significantly decreased hepatic glycogen and muscle glycogen |
SalB can inhibit symptoms of diabetes mellitus in rats, and these effects may partially be correlated with its ISI, glycogen synthesis and antioxidant activities |
| [ | To characterize the effects of |
Two models of SGLT1 induction in rats were used: through diabetes induction with STZ and through dietary carbohydrate manipulation Drinking water was replaced with SFT or RA and blood parameters, liver glycogen and the levels of different proteins in enterocytes quantified |
The increase in SGLT1 localized to the enterocyte brush-border membrane (BBM) induced by STZ treatment was significantly abrogated by treatment with SFT No effects were observed on GLUT2 or GLP-1 levels by SFT SFT and RA significantly inhibited the carbohydrate-induced adaptive increase of SGLT1 in BBM |
SFT and RA modulate the trafficking of SGLT1 to the BBM and may contribute to the control of plasma glucose |
| [ | To investigate that eucalyptol inhibited tubular epithelial cell disjunction and tubulointerstitial fibrosis stimulated by glucose |
Mice were divided into three subgroups (non-diabetic db/m– control, db/db mice and db/db+eucalyptol (10 mg/kg body weight) for 8 weeks Immunohistochemical and Masson trichrome staining of kidney tissues Determination of TGF-β1 secretion and transfection assay |
Eucalyptol inhibited glucose-induced expression of the mesenchymal markers of N-cadherin and α-smooth muscle actin Enhanced induction of E-cadherin and attenuated the induction of connective tissue growth factor and collagen IV by glucose Oral administration of eucalyptol blunted hyperglycemia and proteinuria, reversed tissue levels of E-cadherin, N-cadherin and P-cadherin and the collagen fiber deposition in diabetic kidneys. Furthermore, attenuated the induction of Snail1, β-catenin and integrin-linked kinase 1 (ILK1) in glucose-exposed tubular cells and diabetic kidneys, reversely enhanced glycogen synthase kinase (GSK)-3β expression |
Eucalyptol may antagonize hyperglycemia-induced tubular epithelial derangement and tubulointerstitial fibrosis through blocking ILK1-dependent transcriptional interaction of Snail1/β-catenin |
| [ | To investigate the phytochemical composition of |
SSEO chemical profiling Acute and subchronic antidiabetic potentials using male Swiss Webster mice |
Chemotypes 1 (owned to high linalool content), present at low altitude places of Lebanon and Poland, has shown significantly higher acute and subchronic antidiabetic activities than that of chemotype 5 (owned to high linalyl acetate content) |
SSEOs have shown potential antidiabetic activities, and their EOs might be used in the future as complementary or alternative medicine in the management of diabetes and related complications |
| [ | To examine the effects of lithospermic acid B (LAB) on the prevention of diabetic retinopathy in Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model of T2DM |
LAB (10 or 20 mg/kg) or normal saline were given orally once daily to 24-week-old male OLETF rats for 52 weeks Assessment of fundoscopic findings and vascular endothelial growth factor (VEGF) expression Measurement of glucose metabolism, serum levels of high-sensitivity C-reactive protein (hs-CRP), monocyte chemotactic protein-1 (MCP1), tumor necrosis factor-alpha (TNFα) and urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels |
LAB treatment improved insulin resistance and glucose intolerance; reduced serum s-CRP, MCP1, TNFα, and urinary 8-OHdG levels; and prevented vascular leakage and basement membrane thickening |
Treatment with LAB had a preventive effect on developing diabetic retinopathy |
| [ | To investigate the effect of cryptotanshinone on myocardial fibrosis in diabetic rats |
Male Wistar rats were separated into three groups (control, vehicle-treated STZ-treated rats, and cryptotanshinone-treated STZ-treated rats) |
In STZ-treated rats, FBG levels and heart weight/body weight ratio were markedly increased, but both were not modified by cryptotanshinone Cardiac performance in catheterized STZ-treated rats was improved. The histological results from Masson staining showed that cryptotanshinone attenuated cardiac fibrosis in STZ-treated rats Both the messenger ribonucleic acid (mRNA) and protein levels of the signal transducer and activator of transcription 3 (STAT3), matrix metalloproteinase-9, and connective tissue growth factor were reduced by cryptotanshinone in high glucose-cultured cardiomyocytes |
STAT3 regulates matrix metalloproteinase-9 and connective tissue growth factor expression in diabetic rats with cardiac fibrosis, cryptotanshinone inhibited fibrosis to improve cardiac function by suppressing the STAT3 pathway |
| [ | To screen and explore bioactive constituents from the root of |
Identification of tanshinone IIA (TSIIA) STZ-induced diabetic C57BL/6 mice were injected with TSIIA (10 and 30 mg/kg) |
Treatment of diabetic mice with TSIIA with both doses significantly decreased angiotensin (ANG) II level in serum (from 16.56 ± 1.70 to 10.86 ± 0.68 and 9.14 ± 1.31 pg/mL) and reduced ANG II expression in bone Improved trabecular bone mineral density and microstructure of proximal tibial end, increased trabecular bone area of distal femoral end in diabetic mice |
TSIIA has beneficial effects on bone of diabetic mice and potentially suggested applying |
| [ | To investigate the potential therapeutic function of TSIIA on diabetic cardiomyopathy in an experimental diabetic rat model |
STZ-induced diabetic rats were IP injected with TSIIA for 6 weeks |
Blood glucose concentration was slightly reduced in the low-dose TSIIA treatment group TSIIA injection improved cardiac function and restored the loss of mitochondrial cristae, swollen mitochondrial matrix and disorganized myofibrils in myocardial cells TSIIA injection increased the activity of superoxide dismutase and suppressed the endoplasmic reticulum (ER) stress signaling in STZ-induced diabetic rats |
TSIIA may ameliorate diabetic cardiomyopathy in diabetic rats, possibly via suppressing oxidative stress and ER stress activation |
| [ | To evaluate the therapeutic potential of the polyphenolic acids fraction (PAF) from |
Four groups of rats were orally administrated with an oral dose of 187 mg/kg PAF for 28 days |
PAF induced a significant decrease in FBG, fasting blood insulin (FINS), total cholesterol (TC), triglyceride (TG) and blood urea nitrogen (BUN), and increased ISI in diabetic rats induced by an HFD and a low dose of STZ |
PAF is an effective fraction with antidiabetic potential |
| [ | To investigate the effects and possible mechanisms of the pharmacodynamic interaction between paeonol (Pae) and danshensu (DSS) on cerebrovascular malfunctioning in diabetes |
Diabetic rats were treated with Pae, DSS, and Pae + DSS for 8 weeks Pae, DSS, and Pae + DSS effects on vessel relaxation with or without endothelium as well as on the basal tonus of vessels from normal and diabetic rats Oxidative stress indexes |
The cerebral arteries from diabetic rats show decreased vascular reactivity to acetylcholine (ACh), which was corrected in Pae, DSS, and Pae + DSS treated groups Antagonized relaxation responses increased in DSS and Pae + DSS-treated diabetic groups compared with those in diabetic and Pae-treated diabetic groups Superoxide dismutase activity and thiobarbituric acid reactive substances content significantly changed in the presence of Pae + DSS |
Both Pae and DSS treatments prevent diabetes-induced vascular damage. The combination of Pae and DSS produced significant protective effects through the reduction of oxidative stress and intracellular Ca2+ regulatory mechanisms |
| [ | To investigate the role of AGE-mediated neuroinflammation in learning and memory deficits and the effect of DSS on the cognitive decline in diabetic mice |
C57BL/6 mice were injected intraperitoneally with STZ Sodium salt of DSS was administered at a dose of 15, 30, or 60 mg/kg for 12 weeks |
DSS reduced the mean escape latency and increased the percentage of time spent in the target quadrant DSS partly blocked the expression of receptor of glycation end (RAGE), p-p38, and cyclooxygenase 2 (COX-2), and nuclear factor kappa-light-chain-enhancer of B cells (NF-κB) activation, and inhibited the increase of TNF-α, interleukin 6 (IL-6), and prostaglandin E2 (PGE₂) |
DSS may provide a potential alternative for the prevention of cognitive impairment associated with diabetes by attenuating AGE-mediated neuroinflammation |
| [ | To examine the protective efficacy of Jiangtang decoction (JTD) in diabetic nephropathy (DN) and elucidate the underlying molecular mechanisms |
KK-Ay mice diabetic model administered JTD (12 weeks) Assessment of renal function JTD protective renal effect via pathological staining Determination of inflammatory biomarkers Analysis of phosphoinositide 3-kinase (PI3K)/Akt signaling pathway and NF-κB |
A significant amelioration in glucose and lipid metabolism dysfunction. JTD treatment reduced the accumulation of AGEs and RAGE, upregulated IRS-1, and increased the phosphorylation of both PI3K (p85) and Akt JTD administration reduced the elevated levels of renal inflammatory mediators and decreased the phosphorylation of NF-κB p65 |
JTD might reduce inflammation in DN through the PI3K/Akt and NF-κB signaling pathways |
| [ | To evaluate the effect and potential mechanism of Huangqi-danshen decoction (HDD) in the treatment of DN in a T2DM animal model, db/db mice |
HDD extract was administered orally to db/db mice at a dose of 6.8 g/kg/day for 12 weeks Biochemical and pathological examinations |
HDD substantially reduced urinary albumin excretion and improved renal injury in db/db mice HDD treatment significantly reversed the enhanced mitochondrial fission and PTEN-induced putative kinase 1 (PINK1)/Parkin-mediated mitophagy in the db/db mice |
HDD could protect against T2DM-induced kidney injury, possibly by inhibiting PINK1/Parkin-mediated mitophagy |
| [ | To assess the effectiveness and safety of compound danshen dripping pill (CDDP) in treating patients with nonproliferative diabetic retinopathy (NPDR) |
223 NPDR patients were enrolled Subjects received oral study medications three times daily for 24 weeks The four groups were placebo, low-dose (270 mg), mid-dose (540 mg) and high dose (810 mg herbal medicine) Primary endpoints were changes in fluorescence fundus angiography (FFA) and fundoscopic examination parameters |
For the FFA, the high-dose and mid-dose CDDP groups were 74% and 77%, respectively, significantly higher than 28% in the placebo group For fundoscopic examination, the high-dose and mid-dose CDDP groups were 42% and 59%, respectively, significantly higher than 11% in the placebo group No serious adverse events were observed |
Data demonstrated the therapeutic value and safety of a danshen-containing Chinese herbal medicine in patients with diabetic retinopathy |
| [ | To determine the effectiveness and safety of Tricardin along with physical rehabilitation in diabetic patients with polyneuropathies and to observe the effect of this drug on the quality of life of these patients |
A randomized controlled study on 100 diabetic patients with established polyneuropathies (n = 50 intervention and 50 control) In the control group, usual therapy for diabetes plus physical rehabilitation comprising of foot care education, pain management using transcutaneous electrical nerve stimulation (TENS), nerve gliding exercises for lower limbs, balance and proprioception training was provided Tricardin capsule was administered three times daily for eight weeks (experimental group) Pre and post-treatment quality of life via self-structured questionnaire |
The pretreatment quality of life score was lower in both groups, with 29.54 ± 1.85 (control) and 34.82 ± 4.78 (treatment) Quality of life score improved significantly in the intervention group (134.2 ± 9.74) ( |
Tricardin was found to be a safe and effective treatment option for the management of diabetic polyneuropathies |
| [ | To investigate the involvement of collagen IV (ColIV) and fibronectin (FN) in the occurrence and development of DN and the effects of telmisartan and |
Two hundred and fifty-eight patients with stage IV DN (cases group) and 110 normal healthy subjects (control) Involved patients were subdivided into different groups according to different treatment therapies: (T group: oral telmisartan), (S + T group: |
Glycemic and renal damage indexes indicated trends downwards both in the T group and the S + T group S + T group levels were much lower than the T group (all Fasting blood glucose, 2 h postprandial glucose (2hPPG), glycosylated hemoglobin (HbA1c), blood urea nitrogen, serum creatinine and urinary albumin excretion rate were significant after treatment (all Co1IV and FN in the urine were increased before intervention in the case group compared to the control (all There were remarkable differences in Co1IV and FN levels in the urine when compared among three different intervention groups after treatment ( |
|
| [ | To evaluate the efficacy and safety of |
Determination of the total flavonoid, total phenolic and quercetin contents The effects of 2-month extract intake (500 mg capsule three times a day) as an add-on to daily use of 15 mg glyburide, 2000 mg metformin and 10 mg atorvastatin on the blood levels of fasting blood sugar (FBS), 2hPPG, HbA1c, TC, low-density lipoprotein cholesterol (LDL), TG, high-density lipoprotein (HDL), serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), creatinine and body mass index were studied in 50 patients and compared with the placebo group ( |
Total flavonoid, phenolic, and quercetin contents were 39.76 ± 3.58 mg of rutin equivalents (mean ± SD), 30.33 ± 1.23 mg of gallic acid (mean ± SD) and 0.13 mg, respectively The extract lowered FG, 2hPPG, HbA1c, TC, LDL and TG levels but increased HDL level compared to the placebo ( |
The addition of the extract to statin therapy is safe and further improves lipid profile; however, conduction of more clinical trials are warranted |
Figure 2The chemical structures of several main chemical constituents (source: [58,59,60,61,62,63,64,65,66,67,68]).
Figure 3Schematic diagram representing the development of diabetic nephropathy, cardiomyopathy and nephropathy (adapted from [99,100]).
Figure 4The schematic diagram of PINK1/Parkin-mediated mitophagy (adapted from [101]).